You are here: Welcome to the MPKB » Welcome to the MPKB » Marshall Protocol » Olmesartan (Benicar) » Patient response to olmesartan (Benicar)
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Next revision		Previous revision
Last revisionBoth sides next revision
home:mp:olmesartan:response [01.03.2012] – external edit 127.0.0.1home:mp:olmesartan:response [06.05.2019] – [Patient response to olmesartan (Benicar)] sallieq
Line 1: Line 1:
 ====== Patient response to olmesartan (Benicar)     ====== ====== Patient response to olmesartan (Benicar)     ======
 +
 +<relatedarticles> [[home:patients:grappling_uncertainty|Confronting uncertainty about the Marshall Protocol]],  [[home:physicians:concerns|Physicians' concerns and success rates for 5 Dx]], [[home:starting:physician:reluctant#specific_research|Independent research into Olmesartan]]</article>
 +
  
 Olmesartan (Benicar) has two actions. It palliates symptoms by reducing inflammation, and it activates the innate immune response. Patients who begin the Marshall Protocol (MP) may experience either, both, or neither. According to one rough estimate, 25% of patients who begin the MP experience immediate symptomatic relief when they begin the olmesartan blockade, about 25% feel no different, and the other 50% will experience some adjustment symptoms. Even for MP patients who have a minimal initial reaction to olmesartan, the medication almost always ultimately has strong antibacterial effects resulting in immunopathology. For olmesartan to be effective, it has to be [[dosing|dosed regularly]]: 40mg every 6-8 hours. Olmesartan (Benicar) has two actions. It palliates symptoms by reducing inflammation, and it activates the innate immune response. Patients who begin the Marshall Protocol (MP) may experience either, both, or neither. According to one rough estimate, 25% of patients who begin the MP experience immediate symptomatic relief when they begin the olmesartan blockade, about 25% feel no different, and the other 50% will experience some adjustment symptoms. Even for MP patients who have a minimal initial reaction to olmesartan, the medication almost always ultimately has strong antibacterial effects resulting in immunopathology. For olmesartan to be effective, it has to be [[dosing|dosed regularly]]: 40mg every 6-8 hours.
Line 16: Line 19:
 Once the body's mechanisms for regulating hormones has adjusted to regular doses of olmesartan, patients may find that they experience immunopathology or an increase in symptoms of disease. It is often the case that this is due to olmesartan's molecular actions. In its role as Vitamin D Receptor agonist, olmesartan activates the innate immune response, which leads to the transcription of anti-microbial peptides, the body's broad-spectrum antibacterials. This results in bacterial die-off and an unpleasant increase in symptoms. Once the body's mechanisms for regulating hormones has adjusted to regular doses of olmesartan, patients may find that they experience immunopathology or an increase in symptoms of disease. It is often the case that this is due to olmesartan's molecular actions. In its role as Vitamin D Receptor agonist, olmesartan activates the innate immune response, which leads to the transcription of anti-microbial peptides, the body's broad-spectrum antibacterials. This results in bacterial die-off and an unpleasant increase in symptoms.
  
-Though the immunopathological reaction to olmesartan is near universal in the MP cohort, nothing that would suggest an increase in symptoms is listed in the [[http://medicaidprovider.hhs.mt.gov/pdf/benicar.pdf|monograph for olmesartan]]. In fact, the only adverse event in which olmesartan had a higher incidence than a placebo is for dizziness (3% vs. 1%). However, it should be noted, the patients in these studies were given Benicar only once a day.+Though the immunopathological reaction to olmesartan is near universal in the MP cohort, nothing that would suggest an increase in symptoms is listed in the [[https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021286s020lbl.pdf|monograph for olmesartan]]. In fact, the only adverse event in which olmesartan had a higher incidence than a placebo is for dizziness (3% vs. 1%). However, it should be noted, the patients in these studies were given Benicar only once a day.
  
 This discrepancy underscores how crucial regular dosing of olmesartan is for achieving an immune response. This discrepancy underscores how crucial regular dosing of olmesartan is for achieving an immune response.
Line 35: Line 38:
  
  
-{{tag>olmesartan}}+{{tag>MP olmesartan}}
  
  
home/mp/olmesartan/response.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.